Roche’s Secret Heart Drug Moves Toward Late-Stage Trial

Roche Holding AG is planning a final-stage trial of a drug that taps into a gene mutation to lower cholesterol and heart attack risk beyond what statins such as Pfizer Inc.’s $9.6 billion-selling Lipitor can do.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.